Cogent Biosciences (COGT) Is Up 13.1% After FDA RTOR Nod For Bezuclastinib Combo - Has The Bull Case Changed? [Yahoo! Finance]
Cogent Biosciences (NASDAQ:COGT) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $55.00 price target on the stock.
Cogent Biosciences to Initiate New Drug Application (NDA) Submission for Bezuclastinib Under Real-Time Oncology Review (RTOR)
Cogent Biosciences Announces Anticipated 2026 Commercial and Clinical Milestones for Bezuclastinib and Precision Therapies Portfolio
Cogent Insider Sells $2.5 Million in Stock Amid Staggering 300% Price Surge [Yahoo! Finance]